# Volociximab and Erlotinib in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

> **NCT00278187** · PHASE2 · UNKNOWN · sponsor: **Jonsson Comprehensive Cancer Center**

## Conditions studied

- Lung Cancer

## Interventions

- **BIOLOGICAL:** volociximab
- **DRUG:** erlotinib hydrochloride

## Key facts

- **NCT ID:** NCT00278187
- **Lead sponsor:** Jonsson Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2005-07
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2013-12-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00278187

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00278187, "Volociximab and Erlotinib in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00278187. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*